Recent advances in CAR-T therapy for the treatment of acute myeloid leukemia.

IF 3.4 3区医学 Q2 HEMATOLOGY

Therapeutic Advances in Hematology Pub Date : 2024-07-23 eCollection Date: 2024-01-01 DOI:10.1177/20406207241263489

Chenyu Zha, Jialu Song, Ming Wan, Xiao Lin, Xiaolin He, Ming Wu, Rui Huang

{"title":"Recent advances in CAR-T therapy for the treatment of acute myeloid leukemia.","authors":"Chenyu Zha, Jialu Song, Ming Wan, Xiao Lin, Xiaolin He, Ming Wu, Rui Huang","doi":"10.1177/20406207241263489","DOIUrl":null,"url":null,"abstract":"<p><p>Chimeric antigen receptor T-cell (CAR-T) therapy, which has demonstrated notable efficacy against B-cell malignancies and is approved by the US Food and Drug Administration for clinical use in this context, represents a significant milestone in cancer immunotherapy. However, the efficacy of CAR-T therapy for the treatment of acute myeloid leukemia (AML) is poor. The challenges associated with the application of CAR-T therapy for the clinical treatment of AML include, but are not limited to, nonspecific distribution of AML therapeutic targets, difficulties in the production of CAR-T cells, AML blast cell heterogeneity, the immunosuppressive microenvironment in AML, and treatment-related adverse events. In this review, we summarize the recent findings regarding various therapeutic targets for AML (CD33, CD123, CLL1, CD7, etc.) and the results of the latest clinical studies on these targets. Thereafter, we also discuss the challenges related to CAR-T therapy for AML and some promising strategies for overcoming these challenges, including novel approaches such as gene editing and advances in CAR design.</p>","PeriodicalId":23048,"journal":{"name":"Therapeutic Advances in Hematology","volume":"15 ","pages":"20406207241263489"},"PeriodicalIF":3.4000,"publicationDate":"2024-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11268017/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Therapeutic Advances in Hematology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/20406207241263489","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Chimeric antigen receptor T-cell (CAR-T) therapy, which has demonstrated notable efficacy against B-cell malignancies and is approved by the US Food and Drug Administration for clinical use in this context, represents a significant milestone in cancer immunotherapy. However, the efficacy of CAR-T therapy for the treatment of acute myeloid leukemia (AML) is poor. The challenges associated with the application of CAR-T therapy for the clinical treatment of AML include, but are not limited to, nonspecific distribution of AML therapeutic targets, difficulties in the production of CAR-T cells, AML blast cell heterogeneity, the immunosuppressive microenvironment in AML, and treatment-related adverse events. In this review, we summarize the recent findings regarding various therapeutic targets for AML (CD33, CD123, CLL1, CD7, etc.) and the results of the latest clinical studies on these targets. Thereafter, we also discuss the challenges related to CAR-T therapy for AML and some promising strategies for overcoming these challenges, including novel approaches such as gene editing and advances in CAR design.

查看原文本刊更多论文

治疗急性髓性白血病的 CAR-T 疗法的最新进展。

嵌合抗原受体 T 细胞（CAR-T）疗法对 B 细胞恶性肿瘤有显著疗效，美国食品药品管理局已批准将其用于临床，这是癌症免疫疗法的一个重要里程碑。然而，CAR-T疗法治疗急性髓性白血病（AML）的疗效不佳。应用 CAR-T 疗法临床治疗急性髓性白血病所面临的挑战包括但不限于：急性髓性白血病治疗靶点的非特异性分布、CAR-T 细胞的生产困难、急性髓性白血病爆破细胞的异质性、急性髓性白血病的免疫抑制微环境以及治疗相关的不良反应。在这篇综述中，我们总结了有关急性髓细胞性白血病各种治疗靶点（CD33、CD123、CLL1、CD7 等）的最新发现以及有关这些靶点的最新临床研究结果。随后，我们还讨论了与急性髓细胞白血病 CAR-T 疗法相关的挑战以及克服这些挑战的一些有前景的策略，包括基因编辑等新方法和 CAR 设计方面的进展。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Therapeutic Advances in Hematology HEMATOLOGY-

CiteScore

4.30

自引率

0.00%

发文量

审稿时长

7 weeks

期刊介绍： Therapeutic Advances in Hematology delivers the highest quality peer-reviewed articles, reviews, and scholarly comment on pioneering efforts and innovative studies across all areas of hematology. The journal has a strong clinical and pharmacological focus and is aimed at clinicians and researchers in hematology, providing a forum in print and online for publishing the highest quality articles in this area.